Sponsored by
High-Growth Investing
  •  

Headwaters Dammed

By Tim Beyers May 1, 2008

6 Recommendations

Headwaters' (NYSE: HW) river of revenue and profits was finally dammed yesterday.

Specifically, second-quarter revenue declined 37%, and a $0.59-per-share profit in last year's Q2 became a $0.22-per-share loss this year. Management, meanwhile, cut its full-year earnings guidance from $0.95 to $1.35 a share to between $0.60 and $0.75 per share.

Blame the alternative energy business. Or building products. Or coal. All three units saw lower or flat revenue and earnings. Building products couldn't even manage an operating profit thanks to the housing-led economic meltdown.

But it was the alternative energy segment, which in the past had accounted for the majority of Headwaters' profits, that took the worst beating. Expiring tax credits related to its synfuel business nearly eliminated the need for the division's products. Revenue plummeted 82% as a result.

The good news? None of this has much to do with Headwaters' future prospects. As CEO Kirk Benson told Foolish colleague Rich Smith in October, coal products will likely drive growth over the next five years and alternative energy in the decade beyond that.

Here, "alternative energy" refers to a molecular process called HCAT that transforms unusable heavy oil into light, sweet crude, which is easier for refiners such as Valero  (NYSE: VLO), Sunoco  (NYSE: SUN), and Tesoro  (NYSE: TSO) to process. The demand for light, sweet crude is ever-present and could eventually translate to slick results for Headwaters' bottom line.

There's only one problem. HCAT has hit a snag. Quoting from a company statement:

We introduced HCAT into a third refinery in mid-February. After the trial commenced, a technical constraint arose within the unit and the refinery temporarily suspended the demonstration eight days into the test. During the eight-day trial period, we observed the same positive results previously demonstrated. As of this date, the test has not restarted. We continue to look forward to resumption of the demonstration test, the reintroduction of HCAT and the conclusion of the testing period. [Emphasis added.]

Fingers crossed, then.

Headwaters still holds promise, but only if the hiccups with HCAT halt.

Fuel up with related Foolishness:

Get the best of the Fool delivered to your inbox every Friday

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 635363, ~/articles/articlehandler.aspx, 5/17/2008 7:56:45 AM

Sign up for FREE Motley Fool site access!

Already registered? Login Here

It’s FREE! Enter your email address, and we’ll rush you to the article you're looking for right now.

Privacy / Legal Information

No, thanks

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Related Tickers

Headwaters, Inc.

HW Up! $11.44 +0.29 (+2.60%) 4:02 PM
CAPS Rating:
722 Outperforms
62 Underperforms
Rate This Stock

Major Indices

S&P 5001,425.35+0.13%
DJIA12,986.80 -0.05%
RSL 2K741.17 -0.30%
NASD2,528.85 -0.19%
Updated: 4:02:51 PM
Sponsored by:

The Motley Poll

How would you describe your level of investing experience?

Sponsored by: